A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis

Trial Profile

A Long-term Assessment of the Safety and Efficacy of AMG 827 Subcutaneous Treatment in Subjects with Psoriasis

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2015

At a glance

  • Drugs Brodalumab (Primary)
  • Indications Plaque psoriasis
  • Focus Adverse reactions
  • Sponsors Amgen
  • Most Recent Events

    • 28 Jul 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 17 Mar 2015 According to an Amgen media release, data from this study were presented at the 73rd Annual Meeting of the American Academy of Dermatology (AAD) 2015.
    • 14 Jan 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top